Marijuana Rescheduling Tracker: Where Schedule III Stands
Marijuana is only partly rescheduled. Since April 28, 2026, FDA-approved marijuana products and marijuana handled under a state medical marijuana license are in Schedule III. All other marijuana, including adult-use, stays in Schedule I while a DEA hearing on the broader 2024 proposal waits for the judge's recommended decision.
Where rescheduling stands (checked November 14, 2026)
- State-licensed medical marijuana: Schedule III since April 28, 2026, under 91 FR 22714 (AG Order No. 6754-2026).
- FDA-approved marijuana products: Schedule III under the same order. Synthetic THC and hemp are outside it.
- Adult-use and all other marijuana: Schedule I. The order leaves it there; the broader move proposed in 89 FR 44597 is still before DEA.
Next step: a recommended decision from Chief Administrative Law Judge Derek C. Julius in Hearing Docket No. 26-96. Briefing on the GAO report closed with reply briefs due November 5, 2026. As of November 14, neither DEA's hearing documents page nor DEA's rescheduling page lists a recommended decision. Any change for adult-use marijuana would come in a final rule published in the Federal Register.
Petitions for review of the April order are pending in the U.S. Court of Appeals for the D.C. Circuit, including No. 26-1130, filed by Nebraska, Indiana and Louisiana. The order stays in effect while they are pending.
Rescheduling timeline, every filing and order
Newest at the bottom. Each row links to the document it rests on.
| Date | What happened | Document | Coverage |
|---|---|---|---|
| Oct. 6, 2022 | The President asks the Attorney General and HHS to review how marijuana is scheduled. | 89 FR 44597 (background) | |
| Aug. 29, 2023 | HHS recommends Schedule III to DEA. | 89 FR 44597 (background) | |
| May 21, 2024 | DEA proposes moving marijuana from Schedule I to Schedule III (Docket No. DEA-1362). | 89 FR 44597 | Our coverage |
| Aug. 29, 2024 | First notice of hearing; hearing set for Dec. 2, 2024. | Recited at 91 FR 22778 | |
| Jan. 13, 2025 | The presiding judge stays the 2024 hearing pending an interlocutory appeal. | Recited at 91 FR 22778 | |
| Dec. 18, 2025 | Executive Order 14370, Increasing Medical Marijuana and Cannabidiol Research, directs the Attorney General to finish the Schedule III rulemaking. Published Dec. 23, 2025 at 90 FR 60541. | Cited at 91 FR 22777 | Our coverage |
| Apr. 28, 2026 | Final order in effect: FDA-approved marijuana products and state-licensed medical marijuana move to Schedule III. Signed Apr. 22. | 91 FR 22714 | Our coverage |
| Apr. 28, 2026 | The 2024 hearing is withdrawn and a new hearing is noticed on the broader proposal. | 91 FR 22778; 91 FR 22777 | Our coverage |
| May 22, 2026 | Nebraska, Indiana and Louisiana petition the D.C. Circuit to review the April order. | No. 26-1130 | Our coverage |
| June 2026 | The judge grants Louisiana's motion to withdraw from the hearing. | DEA hearing documents | |
| June 29, 2026 | The hearing opens in Arlington, Virginia (Hearing Docket No. 26-96). | DEA release, June 25, 2026 | Our coverage |
| July 15, 2026 | The hearing closes. | ALJ order, Sept. 29, 2026 | Our coverage |
| July 2026 | The judge orders transcript corrections and post-hearing briefs. | DEA hearing documents | Our coverage |
| Sept. 23, 2026 | GAO publishes GAO-26-108623 on DEA and HHS drug scheduling. | GAO-26-108623 | |
| Sept. 29, 2026 | The judge stays the case while a motion to admit the GAO report is briefed. | Stay and briefing order | |
| Oct. 22, 2026 | The judge admits the GAO report, allows supplemental briefs and denies a motion to reopen the hearing. | ALJ order, Oct. 22, 2026 | Our coverage |
| Nov. 5, 2026 | Reply briefs due; the stay ends by the order's terms. | ALJ order, Oct. 22, 2026 | |
| Nov. 14, 2026 | No recommended decision listed on DEA's pages. | DEA hearing documents |
What Schedule III changes, and what it does not
- Scope. Only FDA-approved marijuana products and marijuana under a state medical license moved. Adult-use marijuana, synthetic THC and hemp did not.
- DEA registration and interstate sales. A Schedule III substance is still a controlled substance that only DEA registrants may handle, so the move did not make interstate sales lawful. The order let medical licensees who applied for registration within 60 days of publication keep operating under their state license while DEA reviews. See our registration coverage.
- Section 280E. The tax code at 26 U.S.C. 280E denies deductions to businesses trafficking in Schedule I or II substances. State-licensed medical marijuana is now in Schedule III; adult-use marijuana is still in Schedule I. Treasury and the IRS described their process for tax guidance on April 23, 2026. This is not tax advice; see the 280E playbook and talk to your tax adviser.
- Banking. The order does not mention banks, and FinCEN has not replaced its 2014 guidance. See the cannabis banking guide.
- Research. Executive Order 14370, titled Increasing Medical Marijuana and Cannabidiol Research, directed the Attorney General to finish the Schedule III rulemaking.
- State law. Federal scheduling does not change state licensing, possession limits or penalties. Check state cannabis and hemp laws.
- Workplace drug testing. Employer policy questions under the two-tier system are covered in rescheduling and workplace rules.
Frequently asked questions
Partly. Since April 28, 2026, FDA-approved marijuana products and marijuana under a state medical marijuana license are in Schedule III. Adult-use marijuana is still in Schedule I.
Moving marijuana from Schedule I, the most restricted category of the Controlled Substances Act, to Schedule III. A Schedule III substance is still controlled: it can be handled only by DEA registrants, and Section 280E, which reaches only Schedule I and II substances, no longer covers it.
Chief Administrative Law Judge Derek C. Julius issues a recommended decision on the broader 2024 proposal. As of November 14, 2026, none is listed on DEA's pages. Any change for adult-use marijuana would come in a final rule published in the Federal Register.
Yes. The April 2026 order leaves adult-use marijuana in Schedule I. State adult-use programs keep operating under state law.
No. The order excludes hemp. Hemp has its own federal change on December 11, 2026, when the total-THC test and the 0.4 mg per container cap take effect.
Sources
- 91 FR 22714, final order placing FDA-approved and state medical marijuana in Schedule III (Apr. 28, 2026)
- 91 FR 22777, notice of hearing (Apr. 28, 2026)
- 91 FR 22778, withdrawal of the 2024 hearing notice (Apr. 28, 2026)
- 89 FR 44597, proposed rule (May 21, 2024)
- DEA, hearing documents for the 2026 proceeding
- DEA press release, June 25, 2026
- ALJ stay and briefing order, Sept. 29, 2026
- ALJ order on the motion to reopen, Oct. 14, 2026
- ALJ order admitting the GAO report, Oct. 22, 2026
- GAO-26-108623
- Petition for review, D.C. Cir. No. 26-1130
- 26 U.S.C. 280E
- Treasury and IRS release, Apr. 23, 2026
Regulatory journalism, not legal advice. CannabisRegulations.ai reports what the law says on the date checked; it does not advise on any business or product. Laws and enforcement change often. For a decision about your products, talk to a licensed attorney in your state. Our lawyer directory lists attorneys; listings are not endorsements.
Checked November 14, 2026 against the Federal Register, DEA and court documents cited above.
This is regulatory journalism, not legal advice. Talk to your counsel.
